| Literature DB >> 26080063 |
Longshan Zhao1, Zhili Xiong1, Xiumei Lu1, Shuning Zheng1, Fang Wang2, Lin Ge2, Guangyue Su3, Jingyu Yang2, Chunfu Wu2.
Abstract
Hydrophilic interaction-ultra high performance liquid chromatography (HILIC-UHPLC) allows the analysis of highly polar metabolites, providing complementary information to reversed-phase (RP) chromatography. By optimization of the preparation and analytical conditions in HILIC mode, HILIC-UHPLC/MS was applied for the global metabolic profiling of rat plasma samples generated in an experimental model of chronic unpredictable mild stress (CUMS), and the concomitant investigation of the protective effect of fluoxetine was also evaluated. Identification of plasma metabolic profiles indicated that significant changes in specific metabolites occurred after fluoxetine exposure, including increased phenylalanine, serine, acetyl-L-carnitine, carnitine and decreased creatine, betaine, proline, tryptophan, tyrosine, C16:0 LPC. Some novel biomarkers from this HILIC-UHPLC/MS approach were betaine, proline, tyrosine creatine and serine compared with the results of RP-UHPLC/MS. The complementary nature of this technique is confirmed and is on agreement with previously published studies.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26080063 PMCID: PMC4469692 DOI: 10.1371/journal.pone.0129146
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Instrumental precision, method repeatability and stabilities of system and plasma samples of HILIC-UHPLC/MS.
| tR
| Precision (RSD, %) | Repeatability (RSD, %) | System stability (RSD, %) | Sample stability (RSD, %) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| tR |
| area | tR |
| area | tR |
| area | A | B | C | |
| 6.0_227.0 | 0.64 | 0.026 | 4.0 | 1.3 | 0.028 | 5.2 | 2.0 | 0.035 | 7.6 | 4.9 | -3.4 | -7.4 |
| 8.8_496.6 | 0.35 | 0.017 | 6.3 | 0.69 | 0.020 | 8.9 | 1.2 | 0.024 | 13 | 6.4 | 9.6 | 12 |
| 7.3_115.9 | 0.23 | 0.016 | 2.7 | 0.38 | 0.018 | 4.5 | 0.66 | 0.020 | 6.0 | 5.8 | 4.3 | 6.8 |
| 2.6_103.7 | 0.27 | 0.024 | 8.9 | 0.44 | 0.026 | 9.4 | 0.89 | 0.026 | 13 | -7.2 | -8.5 | -14 |
| 7.6_257.0 | 0.19 | 0.012 | 4.8 | 0.25 | 0.015 | 5.8 | 0.42 | 0.014 | 8.7 | -5.3 | 4.6 | 4.8 |
Note: A, area at room temperature for 4 h; B, area by post preparative of 24 h; C, area after three freeze-thaw cycles.
Fig 1Base peak intensity (BPI) chromatograms of plasma metabolite profiles from (A) a control rat and (B) a model rat measured by HILIC-UHPLC/MS.
Fig 2(A) Score plot and (B) loading plot derived from PCA model classifying control rats (■) and model rats (▲) based on plasma metabolite profiles measured by HILIC-UHPLC/MS.
Biomarkers related to pathological mechanism of depression based on plasma metabolite profiles measured by HILIC-UHPLC/MS.
| tR (min) | m/z (amu) | Metabolite identification | ANOVA analysis ( | Change trend compared with control rats |
|---|---|---|---|---|
| 8.0 | 131.9 | Creatine | 6.04 E-04 | ↓ |
| 7.6 | 117.8 | Betaine | 1.94 E-04 | ↓ |
| 4.8 | 166.0 | Phenylalanine | 3.09 E-02 | ↑ |
| 7.3 | 115.9 | Proline | 6.60 E-05 | ↓ |
| 7.3 | 105.7 | Serine | 1.46 E-04 | ↑ |
| 4.4 | 204.9 | Tryptophan | 1.10 E-04 | ↓ |
| 6.6 | 181.9 | Tyrosine | 4.31 E-04 | ↓ |
| 7.6 | 203.9 | Acetylcarnitine | 1.30 E-05 | ↑ |
| 6.6 | 162.0 | Carnitine | 3.88 E-05 | ↑ |
| 8.8 | 496.6 | C16: 0 LPC | 1.11 E-02 | ↓ |
| 11.0 | 142.8 | Unidentified | 4.52 E-02 | ↓ |
aMetabolites identified by comparing with database and authentic standards
bMetabolites identified by comparing with literatures and database resources
*p < 0.05
**p < 0.01 and
***p < 0.001.
Fig 4Score plot derived from PLS-DA model classifying (■) control rats, (▲) model rats and (◇) fluoxetine treated rats based on plasma metabolite profiles measured by HILIC-UHPLC/MS.
Fig 5Extracted ion chromatograms of proline from plasma metabolite profiles measured by (a) RP-UPLC-MS and (b) HILIC-UPLC-MS.
Biomarkers related to antidepressant mechanism of fluoxetine based on plasma metabolite profiles measured by HILIC-UHPLC/MS.
| tR (min) | m/z (amu) | Metabolite identification | ANOVA analysis ( | Change trend compared with control rats |
|---|---|---|---|---|
| 8.0 | 131.9 | Creatine | 3.32 E-02 | ↑ |
| 7.6 | 117.8 | Betaine | 2.53 E-03 | ↑ |
| 4.8 | 166.0 | Phenylalanine | 4.36 E-03 | ↓ |
| 7.3 | 115.9 | Proline | 7.84 E-05 | ↑ |
| 7.3 | 105.7 | Serine | 6.25 E-05 | ↓ |
| 4.4 | 204.9 | Tryptophan | 1.18 E-03 | ↑ |
| 6.6 | 181.9 | Tyrosine | 4.22 E-04 | ↑ |
| 8.8 | 496.6 | C16: 0 LPC | 4.10 E-02 | ↑ |
| 8.8 | 159.1 | Unidentified | 4.12 E-03 | ↑ |
aMetabolites identified by comparing with database and authentic standards
bMetabolites identified by comparing with literatures and database resources
*p < 0.05
**p < 0.01 and
***p < 0.001.